Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients

被引：0
|
作者：
Loupakis, F. [1 ,2 ,3 ,4 ,5 ]
Cremolini, C. [1 ,2 ,3 ,4 ,5 ]
Perrone, G. [1 ,2 ,3 ,4 ,5 ]
Stasi, I. [1 ,2 ,3 ,4 ,5 ]
Salvatore, L. [1 ,2 ,3 ,4 ,5 ]
Vincenzi, B. [1 ,2 ,3 ,4 ,5 ]
Ruzzo, A. [1 ,2 ,3 ,4 ,5 ]
Ronzoni, M. [1 ,2 ,3 ,4 ,5 ]
Bencardino, K. [1 ,2 ,3 ,4 ,5 ]
Falcone, A. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Azienda USL 6, Dept Oncol, Livorno, Italy
[2] Campus Biomed Univ, Rome, Italy
[3] Univ Urbino, Dept Biomol Sci, I-61029 Urbino, Italy
[4] Ist Sci San Raffaele, I-20132 Milan, Italy
[5] Univ Pisa, Dept Oncol, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4021
引用
收藏
页数：2
相关论文
共 50 条
  • [1] BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (mCRC) PATIENTS
    Cremolini, C.
    Loupakis, F.
    Perrone, G.
    Ruzzo, A.
    Rulli, E.
    Garavaglia, D.
    Bencardino, K.
    Fornaro, L.
    Vincenzi, B.
    Stasi, I
    Masi, G.
    Baldi, G.
    Floriani, I
    Graziano, F.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 8 - 8
  • [2] BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
    Cremolini, C.
    Loupakis, F.
    Perrone, G.
    Ruzzo, A.
    Rulli, E.
    Bencardino, K.
    Vincenzi, B.
    Salvatore, L.
    Graziano, F.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 356 - 357
  • [3] BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILDTYPE METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Cremolini, C.
    Loupakis, F.
    Perrone, G.
    Ruzzo, A.
    Rulli, E.
    Garavaglia, D.
    Bencardino, K.
    Fornaro, L.
    Vincenzi, B.
    Stasi, I
    Masi, G.
    Santini, D.
    Vasile, E.
    Salvatore, L.
    Baldi, G. G.
    Spoto, C.
    Tonini, G.
    Floriani, I
    Graziano, F.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
  • [4] Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
    Yamaguchi, Toshifumi
    Iwasa, Satoru
    Nagashima, Kengo
    Ikezawa, Nobuaki
    Hamaguchi, Tetsuya
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko
    Kato, Ken
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2016, 36 (07) : 3531 - 3536
  • [5] PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
    Loupakis, Fotios
    Pollina, Luca
    Stasi, Irene
    Ruzzo, Annamaria
    Scartozzi, Mario
    Santini, Daniele
    Masi, Gianluca
    Graziano, Francesco
    Cremolini, Chiara
    Rulli, Eliana
    Canestrari, Emanuele
    Funel, Niccola
    Schiavon, Gaia
    Petrini, Iacopo
    Magnani, Mauro
    Tonini, Giuseppe
    Campani, Daniela
    Floriani, Irene
    Cascinu, Stefano
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2622 - 2629
  • [6] Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer
    Azadeh, Payam
    Mortazavi, Nafiseh
    Tahmasebi, Arezoo
    Kamal, Farnaz Hosseini
    Novin, Kambiz
    CHEMOTHERAPY, 2015, 61 (01) : 51 - 56
  • [7] Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC).
    Kennecke, Hagen F.
    Chen, Leo
    Blanke, C. D.
    Cheung, Winson Y.
    Schaff, Kimberly
    Speers, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [8] Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)
    Ricci, V.
    Vivenza, D.
    Monteverde, M.
    Strola, G.
    Granetto, C.
    Lo Nigro, C.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [9] Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)
    Miraglio, E.
    Ricci, V.
    Vivenza, D.
    Monteverde, M.
    Strola, G.
    Granetto, C.
    Lo Nigro, C.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2015, 26 : 40 - 40
  • [10] Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer
    Hoyle, Martin
    Peters, Jaime
    Crathorne, Louise
    Jones-Hughes, Tracey
    Cooper, Chris
    Napier, Mark
    Hyde, Chris
    VALUE IN HEALTH, 2013, 16 (02) : 288 - 296
12345